Literature DB >> 11212958

Arterial hypertension and cardiac arrhythmias.

M G Hennersdorf1, B E Strauer.   

Abstract

PURPOSE AND DATA IDENTIFICATION: One of the main clinical problems of patients with arterial hypertension is the presence of arrhythmias, especially if left ventricular hypertrophy exists. Recent results from our group and all data available via Med-Line-search have been analysed. The analysis was focused on atrial and ventricular arrhythmias and arrhythmic risk prediction, using non-invasive markers. RESULTS OF ANALYSIS AND
CONCLUSION: Arterial hypertension is a major cause of non-rheumatic atrial fibrillation and other supraventricular arrhythmias. The prevalence of ventricular arrhythmias is increased in hypertensive patients without left ventricular hypertrophy, compared to normotensives. If left ventricular hypertrophy is present, the risk for ventricular tachycardias is quadrupled. The presence of left ventricular hypertrophy is associated with an increase in all-cause mortality by a factor of seven in men and nine in women. In particular, patients with hypertrophy, increased rate of ventricular extrasystoles up to non-sustained ventricular tachycardia and ST-depression in long-term ECG are threatened by sudden cardiac death. At present, it is not possible to safely identify patients with increased risk. Regression of hypertrophy exists along with a decreased rate of ventricular extrasystoles. We hypothesize that by the regression of hypertrophy, the prevalence of sustained ventricular tachycardia decreases and therefore the prognosis of those patients can be improved, although controlled studies are not yet available.

Entities:  

Mesh:

Year:  2001        PMID: 11212958     DOI: 10.1097/00004872-200102000-00002

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  15 in total

1.  Sudden death is associated with a widened paced QRS complex in noncoronary cardiac disease.

Authors:  Per Otto Schueller; Marcus Guenter Hennersdorf; Bodo Eckehard Strauer
Journal:  J Interv Card Electrophysiol       Date:  2006-03       Impact factor: 1.900

Review 2.  Mechano-chemo-transduction in cardiac myocytes.

Authors:  Ye Chen-Izu; Leighton T Izu
Journal:  J Physiol       Date:  2017-03-10       Impact factor: 5.182

Review 3.  [Cardiovascular end organ impairment due to hypertension].

Authors:  C M Schannwell; S Steiner; M G Hennersdorf; B E Strauer
Journal:  Internist (Berl)       Date:  2005-05       Impact factor: 0.743

4.  [Hypertension and heart].

Authors:  M Hennersdorf; C M Schannwell; W Motz
Journal:  Internist (Berl)       Date:  2010-07       Impact factor: 0.743

Review 5.  [The heart in hypertension].

Authors:  M G Hennersdorf; B E Strauer
Journal:  Internist (Berl)       Date:  2007-03       Impact factor: 0.743

Review 6.  [Hypertension and cardiac failure].

Authors:  C M Schannwell; M G Hennersdorf; B E Strauer
Journal:  Internist (Berl)       Date:  2007-09       Impact factor: 0.743

7.  A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling.

Authors:  Raghu S Nagalingam; Nagalingam R Sundaresan; Mahesh P Gupta; David L Geenen; R John Solaro; Madhu Gupta
Journal:  J Biol Chem       Date:  2013-02-27       Impact factor: 5.157

Review 8.  Sudden adult death.

Authors:  Neil E I Langlois
Journal:  Forensic Sci Med Pathol       Date:  2009-07-18       Impact factor: 2.007

9.  Deficiency of cardiomyocyte-specific microRNA-378 contributes to the development of cardiac fibrosis involving a transforming growth factor β (TGFβ1)-dependent paracrine mechanism.

Authors:  Raghu S Nagalingam; Nagalingam R Sundaresan; Mariam Noor; Mahesh P Gupta; R John Solaro; Madhu Gupta
Journal:  J Biol Chem       Date:  2014-08-07       Impact factor: 5.157

10.  The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis.

Authors:  Shaosong Zhang; Carla Weinheimer; Michael Courtois; Attila Kovacs; Cindy E Zhang; Alec M Cheng; Yibin Wang; Anthony J Muslin
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.